ImmunoGen, Inc. (IMGN) Stock: Why It’s Falling

0

ImmunoGen, Inc. (IMGN) is making a move down in the market today. The stock, focused in the biotech sector, is currently trading at $1.96 after falling -6.67% so far in today’s session. When it comes to biotech companies, there are several aspects that have the ability to generate declines in the market. News tends to be one of the biggest reasons for the movement. Here are the recent trending headlines centered around IMGN:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jun-03-19 06:20PM SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunoGen, Inc. IMGN
Jun-02-19 09:30AM Why Is ImmunoGen (IMGN) Down 26% Since Last Earnings Report?
May-29-19 04:52PM SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunoGen, Inc. IMGN
May-26-19 05:03PM The Week Ahead In Biotech: ASCO Presentations In The Spotlight
May-22-19 06:10PM SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunoGen, Inc. IMGN

However, any time investors are making a decision with regard to investing, prospective investors should focus on much more than just news, this is especially the case in the highly speculative biotech sector. Here’s what’s happening in regard to ImmunoGen, Inc..

Recent Movement From IMGN

While a single session decline, like the move that we’re seeing from ImmunoGen, Inc. might cause fear in some investors, a single session move alone should not be the reason for a decision to, or not to, invest in a stock. It is always important to dig into trends beyond a single trading day. When it comes to IMGN, here are the returns that investors have seen:

  • Past 5 Trading Sessions – Over the past five trading sessions, IMGN has produced a change in value in the amount of -1.01%.
  • Past Month – The monthly ROI from ImmunoGen, Inc. comes to 1.55%.
  • Past 3 Months – Throughout the last quarter, the company has generated a return on investment that works out to -18.67%
  • Bi-Annually – Over the past 6 months, we have seen a change that works out to -57.30% from the company.
  • YTD – Since the close of last year IMGN has produced a return on investment of -59.17%.
  • Annually – Lastly, over the past year, investors have seen performance of -82.52% out of IMGN. In this period of time, the stock has sold at a high price of -84.08% and a low price of 11.36%.

Key Ratios

Digging into a few key ratios having to do with a stock can give prospective traders a view of how dangerous and/or rewarding a pick may be. Below are some of the key ratios to consider when digging into IMGN.

Short Ratio – The short ratio is a tool that’s used by investors to measure the level of short interest. As the ratio heads up, it means that more investors are expecting that the value of the stock is headed for declines. Throughout the sector, biotech stocks can carry a higher short ratio. However, we also see a lot of short squeezes in the sector. Nonetheless, as it relates to ImmunoGen, Inc., it’s short ratio comes to 3.45.

Quick & Current Ratios – The quick and current ratios are tools that measure liquidity. Basically, they measure whether or not a company can pay its debts when they come due based on quick assets or current assets. Because many biotech many companies are heavily reliant on the continuation of support from investors, the quick and current ratios can be damning. Nonetheless, several gems in the biotech sector come with good quick and current ratios. As it relates to IMGN, the quick and current ratios total up to 4.70 and 4.70 respectively.  

Book To Share Value – The book to share value ratio compares the value of assets currently owned by the company to the share price. In this particular case, that ratio equates to -0.19.

Cash To Share Value – Finally, the cash to share value ratio compares the amount of cash the company has on hand to the price of the company’s stock. Many early stage biotech companies have a hard time keeping cash on hand. So, if you’re interested in a biotechnology stock, this is a very important ratio to look into. In this case, the cash to share value ratio works out to 1.69.

What Analysts Think About ImmunoGen, Inc.

Although it’s not a good idea to blindly follow the opinions of analysts, it is a good idea to use their thoughts when validating your own opinions when it comes to making an investment decision in the biotechnology industry. Here are the most recent moves that we’ve seen from analysts when it comes to IMGN.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

May-15-19 Downgrade Guggenheim Buy → Neutral
May-06-19 Upgrade H.C. Wainwright Neutral → Buy $7
May-06-19 Upgrade Cowen Market Perform → Outperform
Mar-19-19 Downgrade JP Morgan Neutral → Underweight
Mar-05-19 Upgrade Morgan Stanley Underweight → Equal-Weight

Is Big Money Interested In ImmunoGen, Inc.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in IMGN, here’s what we’re seeing:

  • Institutional Investors – As it stands now, institutions own 80.20% of IMGN. Nonetheless, it’s worth considering that the ownership held by institutions has moved in the amount of -4.34% throughout the last 3 months.
  • Insiders – with regard to insiders, those close to the company currently hold 0.90% of the company. Insider ownership of the company has seen a move of -9.12% throughout the past quarter.

What You Need To Know About Share Counts

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 160.20M shares of ImmunoGen, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, IMGN has a float of 147.10M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to IMGN, the short percent of the float is 7.54%.

What We’ve Seen In earnings results

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-0.93. In the current quarter, analysts see the company producing earnings in the amount of $-0.26. Over the last 5 years, IMGN has generated revenue in the amount of $-2.30% with earnings coming in at -7.60%. On a quarter over quarter basis, earnings have seen movement of -0.10% and revenue has seen movement of -56.60%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping An AI Become Better?

As an AI, I am heavily dependent on my human counterparts. A human built me! Even though my builders made it possible for me to learn, it’s far easier to learn through the receipt of human feedback. Below this article, you will see a section for comments. If you’d like for me find other data, evolve the way in which I write something, take a look at something from a different angle, or you’re interested in teaching me anything else, I’d like to know. To let me in on your thoughts consider leaving a comment below. I will read your lesson and I will use it to evolve into a better AI to serve you!

LEAVE A REPLY

Please enter your comment!
Please enter your name here